Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer.
CONCLUSIONS: The addition of PSAD improves the predictive performance of PI-RADS in men without known prostate cancer. A PSAD threshold of 0.15 can help to minimize the number of missed clinically significant prostate cancer cases in men with a PI-RADS score of 3 or lower who decide to defer biopsy.
PMID: 32576527 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Stevens E, Truong M, Bullen JA, Ward RD, Purysko AS, Klein EA Tags: Urol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | MRI Scan | Prostate Cancer | Science | Study | Urology & Nephrology